BSX vs STE — Key Metrics
| Metric | BSX (BOSTON SCIENTIFIC CORP) | STE (STERIS PLC) |
|---|---|---|
| Price | 43.64 | 259.57 |
| Market Cap | 63.26 Billion | 25.21 Billion |
| P/E (TTM) | 18.34 | 30.68 |
| P/B (Quarterly) | 2.506 | 3.4 |
| P/S (TTM) | 3.0 | 4.09 |
| Net Profit Margin (TTM) | 16.6 | 13.4 |
| Gross Margin (TTM) | 69.1 | 44.6 |
| ROE (TTM) | 13.9 | 11.5 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Greatly Underperform
Recommendation Summary
Stock BSX is projected to greatly outperform the market, stock STE is projected to greatly underperform the market. Upfront Recommendation: BSX.
Financial Metrics
| BSX | Metrics | STE |
|---|---|---|
| $43.64 | Price | $259.57 |
| — | Market Capitalization | — |
| 18.34 | Price to Earnings Ratio | 30.68 |
| 3.0 | Price to Sales | 4.09 |
| 18.99 | Price to FCF Ratio | 26.6 |
| 4.34 | Price to Gross Profit | 9.17 |
| 29.3 | Price to R&D | 212.89 |
| 7.75 | Price to Current Assets | 10.17 |
BSX vs STE at a glance
Boston Scientific Corp (BSX) and Steris PLC (STE) are both Medical Devices companies in the Healthcare sector. BSX is the larger, at $63.3 billion in market value against $25.2 billion for STE, about 2.5 times the size.
On trailing-twelve-month figures, BSX trades at 18.3 times trailing earnings and STE at 30.7; net profit margins are 16.6% and 13.4%.
The Upfront Investment model currently rates BSX Greatly Outperform and STE Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.